Seegene submits COVID-19, flu assay for FDA EUA

March 5, 2021

Seegene has submitted its Allplex SARS-CoV-2/FluA/FluB/RSV Assay to the U.S. Food and Drug Administration for emergency use authorization (EUA), according to a company news release.

Seegene's Allplex SARS-CoV-2/FluA/FluB/RSV Assay is a real-time RT-PCR assay that can simultaneously detect and differentiate 8 target genes including Flu A, Flu B, RSV A/B and three different target genes of COVID-19 (S gene, RdRP gene and N gene). The assay also includes dual targets for internal control (endogenous and exogenous respectively) in the same reaction tube.

The Allplex SARS-CoV-2/FluA/FluB/RSV Assay is currently available in Europe and elsewhere around the world.

Visit Seegene for more news

About the Author

Sign up for our eNewsletters
Get the latest news and updates